CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

GlobeNewswire Pharma
Original article

CHMP recommends EU approval of Roche’s Susvimo, the first continuous delivery treatment for neovascular age-related macular degeneration (nAMD)

ranibizumab
Related Companies

Read the original article

Published by GlobeNewswire Pharma on July 24, 2026 10:15 AM

Read Original